New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:00 EDTXOMAXOMA Phase III gevokizumab trial likely to miss endpoint, says Summer Street
Summer Street believes Xoma's Phase III trial for gevokizumab will likely not meet the primary endpoint of being effective in treating eye involvement in patients with BehÁetís disease. The firm says prior clinical trials indicate that the product is only a weak anti-inflammatory agent.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
07:57 EDTXOMAXOMA volatility elevated
Subscribe for More Information
06:04 EDTXOMAStocks with implied volatility above IV index mean; ZNGA XOMA
Stocks with implied volatility above IV index mean; Zynga (ZNGA) 60, XOMA (XOMA) 253 according to iVolatility.
July 1, 2015
06:00 EDTXOMAStocks with implied volatility above IV index mean; NBG XOMA
Subscribe for More Information
June 30, 2015
06:02 EDTXOMAStocks with implied volatility above IV index mean; YELP XOMA
Subscribe for More Information
June 29, 2015
05:51 EDTXOMAStocks with implied volatility movement; XOMA EXEL
Subscribe for More Information
June 26, 2015
09:41 EDTXOMAXOMA mentioned positively by Biotech Insider
06:05 EDTXOMAStocks with implied volatility above IV index mean; XOMA NBG
Subscribe for More Information
June 25, 2015
05:57 EDTXOMAStocks with implied volatility above IV index mean; XOMA YELP
Subscribe for More Information
June 24, 2015
05:57 EDTXOMAStocks with implied volatility above IV index mean; XOMA THC
Stocks with implied volatility above IV index mean; XOMA (XOMA) 169, Tenet (THC) 51 according to iVolatility.
June 23, 2015
05:57 EDTXOMAStocks with implied volatility above IV index mean; XOMA YELP
Subscribe for More Information
June 22, 2015
14:08 EDTXOMAXOMA calls active as shares rally
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use